English
简体中文
Total: £ 56.28
Published Date: 2025-10-16 | Pages: 137 | Tables: 137 | Pharma & Healthcare
The global Treatment of PNH market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Treatment of paroxysmal nocturnal hemoglobinuria (PNH) focuses on controlling the abnormal destruction of red blood cells caused by complement system dysregulation. The mainstay of treatment involves complement inhibitors, such as Eculizumab and Ravulizumab, which block complement protein C5 to prevent the formation of the membrane attack complex (MAC), reducing hemolysis and the risk of blood clots. In severe cases, supportive care like blood transfusions, iron supplementation, or bone marrow transplantation may be needed.
From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Treatment of PNH leading manufacturers including Novartis, Alexion Pharmaceuticals, Roche, Apellis Pharmaceuticals, Amgen, Samsung Bioepis, etc., dominate supply; the top five capture approximately % of global revenue, with Novartis leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Treatment of PNH market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Novartis
Alexion Pharmaceuticals
Roche
Apellis Pharmaceuticals
Amgen
Samsung Bioepis
Segment by Type
Complement Inhibitors
Supportive Care
Others
Segment by Application
Hospital
Clinic
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Treatment of PNH study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Treatment of PNH: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Treatment of PNH Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Complement Inhibitors
1.2.3 Supportive Care
1.2.4 Others
1.3 Market Segmentation by Application
1.3.1 Global Treatment of PNH Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Treatment of PNH Revenue Estimates and Forecasts 2020-2031
2.2 Global Treatment of PNH Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Treatment of PNH Sales Estimates and Forecasts 2020-2031
2.4 Global Treatment of PNH Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Treatment of PNH Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Treatment of PNH Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Complement Inhibitors Market Size by Manufacturers
3.5.2 Supportive Care Market Size by Manufacturers
3.5.3 Others Market Size by Manufacturers
3.6 Global Treatment of PNH Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Treatment of PNH Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Treatment of PNH Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Treatment of PNH Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Treatment of PNH Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Treatment of PNH Sales and Revenue by Type (2020-2031)
6.4 North America Treatment of PNH Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Treatment of PNH Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Treatment of PNH Sales and Revenue by Type (2020-2031)
7.4 Europe Treatment of PNH Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Treatment of PNH Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Treatment of PNH Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Treatment of PNH Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Treatment of PNH Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Treatment of PNH Sales and Revenue by Type (2020-2031)
9.4 Central and South America Treatment of PNH Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Treatment of PNH Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Treatment of PNH Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Treatment of PNH Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Treatment of PNH Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Novartis
11.1.1 Novartis Corporation Information
11.1.2 Novartis Business Overview
11.1.3 Novartis Treatment of PNH Product Models, Descriptions and Specifications
11.1.4 Novartis Treatment of PNH Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Novartis Treatment of PNH Sales by Product in 2024
11.1.6 Novartis Treatment of PNH Sales by Application in 2024
11.1.7 Novartis Treatment of PNH Sales by Geographic Area in 2024
11.1.8 Novartis Treatment of PNH SWOT Analysis
11.1.9 Novartis Recent Developments
11.2 Alexion Pharmaceuticals
11.2.1 Alexion Pharmaceuticals Corporation Information
11.2.2 Alexion Pharmaceuticals Business Overview
11.2.3 Alexion Pharmaceuticals Treatment of PNH Product Models, Descriptions and Specifications
11.2.4 Alexion Pharmaceuticals Treatment of PNH Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Alexion Pharmaceuticals Treatment of PNH Sales by Product in 2024
11.2.6 Alexion Pharmaceuticals Treatment of PNH Sales by Application in 2024
11.2.7 Alexion Pharmaceuticals Treatment of PNH Sales by Geographic Area in 2024
11.2.8 Alexion Pharmaceuticals Treatment of PNH SWOT Analysis
11.2.9 Alexion Pharmaceuticals Recent Developments
11.3 Roche
11.3.1 Roche Corporation Information
11.3.2 Roche Business Overview
11.3.3 Roche Treatment of PNH Product Models, Descriptions and Specifications
11.3.4 Roche Treatment of PNH Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Roche Treatment of PNH Sales by Product in 2024
11.3.6 Roche Treatment of PNH Sales by Application in 2024
11.3.7 Roche Treatment of PNH Sales by Geographic Area in 2024
11.3.8 Roche Treatment of PNH SWOT Analysis
11.3.9 Roche Recent Developments
11.4 Apellis Pharmaceuticals
11.4.1 Apellis Pharmaceuticals Corporation Information
11.4.2 Apellis Pharmaceuticals Business Overview
11.4.3 Apellis Pharmaceuticals Treatment of PNH Product Models, Descriptions and Specifications
11.4.4 Apellis Pharmaceuticals Treatment of PNH Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Apellis Pharmaceuticals Treatment of PNH Sales by Product in 2024
11.4.6 Apellis Pharmaceuticals Treatment of PNH Sales by Application in 2024
11.4.7 Apellis Pharmaceuticals Treatment of PNH Sales by Geographic Area in 2024
11.4.8 Apellis Pharmaceuticals Treatment of PNH SWOT Analysis
11.4.9 Apellis Pharmaceuticals Recent Developments
11.5 Amgen
11.5.1 Amgen Corporation Information
11.5.2 Amgen Business Overview
11.5.3 Amgen Treatment of PNH Product Models, Descriptions and Specifications
11.5.4 Amgen Treatment of PNH Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Amgen Treatment of PNH Sales by Product in 2024
11.5.6 Amgen Treatment of PNH Sales by Application in 2024
11.5.7 Amgen Treatment of PNH Sales by Geographic Area in 2024
11.5.8 Amgen Treatment of PNH SWOT Analysis
11.5.9 Amgen Recent Developments
11.6 Samsung Bioepis
11.6.1 Samsung Bioepis Corporation Information
11.6.2 Samsung Bioepis Business Overview
11.6.3 Samsung Bioepis Treatment of PNH Product Models, Descriptions and Specifications
11.6.4 Samsung Bioepis Treatment of PNH Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Samsung Bioepis Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Treatment of PNH Industry Chain
12.2 Treatment of PNH Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Treatment of PNH Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Treatment of PNH Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Treatment of PNH Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Treatment of PNH Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Treatment of PNH Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Treatment of PNH Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Treatment of PNH Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Treatment of PNH Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Treatment of PNH Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Treatment of PNH Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Treatment of PNH Sales by Region (2020-2025) & (K Units)
Table 8. Global Treatment of PNH Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Treatment of PNH Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Treatment of PNH Sales Share by Manufacturers (2020-2025)
Table 12. Global Treatment of PNH Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Treatment of PNH Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Treatment of PNH by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Treatment of PNH as of 2024)
Table 16. Global Treatment of PNH Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Treatment of PNH Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Treatment of PNH Manufacturing Base and Headquarters
Table 19. Global Treatment of PNH Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Treatment of PNH Sales by Type (2020-2025) & (K Units)
Table 23. Global Treatment of PNH Sales by Type (2026-2031) & (K Units)
Table 24. Global Treatment of PNH Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Treatment of PNH Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Treatment of PNH ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Treatment of PNH Sales by Application (2020-2025) & (K Units)
Table 29. Global Treatment of PNH Sales by Application (2026-2031) & (K Units)
Table 30. Treatment of PNH High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Treatment of PNH Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Treatment of PNH Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Treatment of PNH ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Treatment of PNH Growth Accelerators and Market Barriers
Table 37. North America Treatment of PNH Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Treatment of PNH Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Treatment of PNH Growth Accelerators and Market Barriers
Table 40. Europe Treatment of PNH Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Treatment of PNH Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Treatment of PNH Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Treatment of PNH Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Treatment of PNH Growth Accelerators and Market Barriers
Table 45. Southeast Asia Treatment of PNH Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Treatment of PNH Investment Opportunities and Key Challenges
Table 47. Central and South America Treatment of PNH Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Treatment of PNH Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Treatment of PNH Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Novartis Corporation Information
Table 51. Novartis Description and Major Businesses
Table 52. Novartis Product Models, Descriptions and Specifications
Table 53. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Novartis Sales Value Proportion by Product in 2024
Table 55. Novartis Sales Value Proportion by Application in 2024
Table 56. Novartis Sales Value Proportion by Geographic Area in 2024
Table 57. Novartis Treatment of PNH SWOT Analysis
Table 58. Novartis Recent Developments
Table 59. Alexion Pharmaceuticals Corporation Information
Table 60. Alexion Pharmaceuticals Description and Major Businesses
Table 61. Alexion Pharmaceuticals Product Models, Descriptions and Specifications
Table 62. Alexion Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Alexion Pharmaceuticals Sales Value Proportion by Product in 2024
Table 64. Alexion Pharmaceuticals Sales Value Proportion by Application in 2024
Table 65. Alexion Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 66. Alexion Pharmaceuticals Treatment of PNH SWOT Analysis
Table 67. Alexion Pharmaceuticals Recent Developments
Table 68. Roche Corporation Information
Table 69. Roche Description and Major Businesses
Table 70. Roche Product Models, Descriptions and Specifications
Table 71. Roche Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Roche Sales Value Proportion by Product in 2024
Table 73. Roche Sales Value Proportion by Application in 2024
Table 74. Roche Sales Value Proportion by Geographic Area in 2024
Table 75. Roche Treatment of PNH SWOT Analysis
Table 76. Roche Recent Developments
Table 77. Apellis Pharmaceuticals Corporation Information
Table 78. Apellis Pharmaceuticals Description and Major Businesses
Table 79. Apellis Pharmaceuticals Product Models, Descriptions and Specifications
Table 80. Apellis Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Apellis Pharmaceuticals Sales Value Proportion by Product in 2024
Table 82. Apellis Pharmaceuticals Sales Value Proportion by Application in 2024
Table 83. Apellis Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 84. Apellis Pharmaceuticals Treatment of PNH SWOT Analysis
Table 85. Apellis Pharmaceuticals Recent Developments
Table 86. Amgen Corporation Information
Table 87. Amgen Description and Major Businesses
Table 88. Amgen Product Models, Descriptions and Specifications
Table 89. Amgen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Amgen Sales Value Proportion by Product in 2024
Table 91. Amgen Sales Value Proportion by Application in 2024
Table 92. Amgen Sales Value Proportion by Geographic Area in 2024
Table 93. Amgen Treatment of PNH SWOT Analysis
Table 94. Amgen Recent Developments
Table 95. Samsung Bioepis Corporation Information
Table 96. Samsung Bioepis Description and Major Businesses
Table 97. Samsung Bioepis Product Models, Descriptions and Specifications
Table 98. Samsung Bioepis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Samsung Bioepis Recent Developments
Table 100. Key Raw Materials Distribution
Table 101. Raw Materials Key Suppliers
Table 102. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 103. Milestones in Production Technology Evolution
Table 104. Distributors List
Table 105. Market Trends and Market Evolution
Table 106. Market Drivers and Opportunities
Table 107. Market Challenges, Risks, and Restraints
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Treatment of PNH Product Picture
Figure 2. Global Treatment of PNH Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Complement Inhibitors Product Picture
Figure 4. Supportive Care Product Picture
Figure 5. Others Product Picture
Figure 6. Global Treatment of PNH Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital
Figure 8. Clinic
Figure 9. Other
Figure 10. Treatment of PNH Report Years Considered
Figure 11. Global Treatment of PNH Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Treatment of PNH Revenue (2020-2031) & (US$ Million)
Figure 13. Global Treatment of PNH Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Treatment of PNH Revenue Market Share by Region (2020-2031)
Figure 15. Global Treatment of PNH Sales (2020-2031) & (K Units)
Figure 16. Global Treatment of PNH Sales (CAGR) by Region (2020-2031) (K Units)
Figure 17. Global Treatment of PNH Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers Treatment of PNH Sales Volume Market Share in 2024
Figure 19. Global Treatment of PNH Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Complement Inhibitors Revenue Market Share by Manufacturer in 2024
Figure 22. Supportive Care Revenue Market Share by Manufacturer in 2024
Figure 23. Others Revenue Market Share by Manufacturer in 2024
Figure 24. Global Treatment of PNH Sales Market Share by Type (2020-2031)
Figure 25. Global Treatment of PNH Revenue Market Share by Type (2020-2031)
Figure 26. Global Treatment of PNH Sales Market Share by Application (2020-2031)
Figure 27. Global Treatment of PNH Revenue Market Share by Application (2020-2031)
Figure 28. North America Treatment of PNH Sales YoY (2020-2031) & (K Units)
Figure 29. North America Treatment of PNH Revenue YoY (2020-2031) & (US$ Million)
Figure 30. North America Top 5 Manufacturers Treatment of PNH Sales Revenue (US$ Million) in 2024
Figure 31. North America Treatment of PNH Sales Volume (K Units) by Type (2020- 2031)
Figure 32. North America Treatment of PNH Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 33. North America Treatment of PNH Sales Volume (K Units) by Application (2020-2031)
Figure 34. North America Treatment of PNH Sales Revenue (US$ Million) by Application (2020-2031)
Figure 35. US Treatment of PNH Revenue (2020-2031) & (US$ Million)
Figure 36. Canada Treatment of PNH Revenue (2020-2031) & (US$ Million)
Figure 37. Mexico Treatment of PNH Revenue (2020-2031) & (US$ Million)
Figure 38. Europe Treatment of PNH Sales YoY (2020-2031) & (K Units)
Figure 39. Europe Treatment of PNH Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Europe Top 5 Manufacturers Treatment of PNH Sales Revenue (US$ Million) in 2024
Figure 41. Europe Treatment of PNH Sales Volume (K Units) by Type (2020-2031)
Figure 42. Europe Treatment of PNH Sales Revenue (US$ Million) by Type (2020-2031)
Figure 43. Europe Treatment of PNH Sales Volume (K Units) by Application (2020-2031)
Figure 44. Europe Treatment of PNH Sales Revenue (US$ Million) by Application (2020-2031)
Figure 45. Germany Treatment of PNH Revenue (2020-2031) & (US$ Million)
Figure 46. France Treatment of PNH Revenue (2020-2031) & (US$ Million)
Figure 47. U.K. Treatment of PNH Revenue (2020-2031) & (US$ Million)
Figure 48. Italy Treatment of PNH Revenue (2020-2031) & (US$ Million)
Figure 49. Russia Treatment of PNH Revenue (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Treatment of PNH Sales YoY (2020-2031) & (K Units)
Figure 51. Asia-Pacific Treatment of PNH Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Top 8 Manufacturers Treatment of PNH Sales Revenue (US$ Million) in 2024
Figure 53. Asia-Pacific Treatment of PNH Sales Volume (K Units) by Type (2020- 2031)
Figure 54. Asia-Pacific Treatment of PNH Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 55. Asia-Pacific Treatment of PNH Sales Volume (K Units) by Application (2020-2031)
Figure 56. Asia-Pacific Treatment of PNH Sales Revenue (US$ Million) by Application (2020-2031)
Figure 57. Indonesia Treatment of PNH Revenue (2020-2031) & (US$ Million)
Figure 58. Japan Treatment of PNH Revenue (2020-2031) & (US$ Million)
Figure 59. South Korea Treatment of PNH Revenue (2020-2031) & (US$ Million)
Figure 60. China Taiwan Treatment of PNH Revenue (2020-2031) & (US$ Million)
Figure 61. India Treatment of PNH Revenue (2020-2031) & (US$ Million)
Figure 62. Central and South America Treatment of PNH Sales YoY (2020-2031) & (K Units)
Figure 63. Central and South America Treatment of PNH Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Central and South America Top 5 Manufacturers Treatment of PNH Sales Revenue (US$ Million) in 2024
Figure 65. Central and South America Treatment of PNH Sales Volume (K Units) by Type (2021-2031)
Figure 66. Central and South America Treatment of PNH Sales Revenue (US$ Million) by Type (2020-2031)
Figure 67. Central and South America Treatment of PNH Sales Volume (K Units) by Application (2020-2031)
Figure 68. Central and South America Treatment of PNH Sales Revenue (US$ Million) by Application (2020-2031)
Figure 69. Brazil Treatment of PNH Revenue (2020-2025) & (US$ Million)
Figure 70. Argentina Treatment of PNH Revenue (2020-2025) & (US$ Million)
Figure 71. Middle East, and Africa Treatment of PNH Sales YoY (2020-2031) & (K Units)
Figure 72. Middle East and Africa Treatment of PNH Revenue YoY (2020-2031) & (US$ Million)
Figure 73. Middle East and Africa Top 5 Manufacturers Treatment of PNH Sales Revenue (US$ Million) in 2024
Figure 74. Middle East and Africa Treatment of PNH Sales Volume (K Units) by Type (2021-2031)
Figure 75. South America Treatment of PNH Sales Revenue (US$ Million) by Type (2020-2031)
Figure 76. Middle East and Africa Treatment of PNH Sales Volume (K Units) by Application (2020-2031)
Figure 77. Middle East and Africa Treatment of PNH Sales Revenue (US$ Million) by Application (2020-2031)
Figure 78. GCC Countries Treatment of PNH Revenue (2020-2025) & (US$ Million)
Figure 79. Turkey Treatment of PNH Revenue (2020-2025) & (US$ Million)
Figure 80. Egypt Treatment of PNH Revenue (2020-2025) & (US$ Million)
Figure 81. South Africa Treatment of PNH Revenue (2020-2025) & (US$ Million)
Figure 82. Treatment of PNH Industry Chain Mapping
Figure 83. Regional Treatment of PNH Manufacturing Base Distribution (%)
Figure 84. Global Treatment of PNH Production Market Share by Region (2020-2031)
Figure 85. Treatment of PNH Production Process
Figure 86. Regional Treatment of PNH Production Cost Structure
Figure 87. Channels of Distribution (Direct Vs Distribution)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed
